Staggered, Chemo-Immunotherapy With Durvalumab, MEDI4736 Pemetrexed & Carboplatin (PC) for Metastatic Non-Squamous NSCLC

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2020
This is a Phase II, open label, randomized study of durvalumab in combination with pemetrexed and carboplatin in eligible adult patients with locally advanced or metastatic non-small cell lung cancer. The study will focus on the efficacy of two alternative staggered dosing regimens.
Epistemonikos ID: 7b5c3447275f35643b832f445ee4f92b14130666
First added on: May 06, 2024